VUMC-led COVID-19 clinical trial platform goes international
The ACTIV-4 Host Tissue clinical trial platform, which is designed to investigate therapies targeting the host tissue response to COVID-19 to mitigate lung injury, is now being expanded internationally.
By Bill Snyder